• 1
    Ingui BJ, Rogers MA. Searching for clinical prediction rules in MEDLINE. J. Am. Med. Inform. Assoc. 2001; 8: 391397.
  • 2
    Israel JA. Remission in depression: Definition and initial treatment approaches. J. Psychopharmacol. 2006; 20: 510.
  • 3
    Frank E, Prien RF, Jarrett RB et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch. Gen. Psychiatry 1991; 48: 851855.
  • 4
    Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: Remission and beyond. JAMA 2003; 289: 31523160.
  • 5
    Henkel V, Seemuller F, Obermeier M et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J. Affect. Disord. 2009; 115: 439449.
  • 6
    Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J. Clin. Psychiatry 2003; 64: 413420.
  • 7
    Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. J. Clin. Psychiatry 2009; 70: 344353.
  • 8
    Tadic A, Helmreich I, Mergl R et al. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J. Affect. Disord. 2010; 120: 8693.
  • 9
    van Calker D, Zobel I, Dykierek P et al. Time course of response to antidepressants: Predictive value of early improvement and effect of additional psychotherapy. J. Affect. Disord. 2009; 114: 243253.
  • 10
    Lin CH, Lane HY, Chen CC, Juo SH, Yen CF. Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. Psychiatry Clin. Neurosci. 2011; 65: 510517.
  • 11
    Lin CH, Lane HY, Chen CC, Juo SH, Yen CF. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J. Clin. Psychopharmacol. 2011; 31: 187193.
  • 12
    APA. American Psychiatric Association: Structured Clinical Interview for DSM-IV. American Psychiatric Press, Washington, DC, 1994.
  • 13
    Guy W. ECDEU Assessment Manual for Psychopharmacology. DHEW Publication, 76338, Washington, DC, 1976.
  • 14
    Stokes PE. Fluoxetine: a five-year review. Clin. Ther. 1993; 15: 216243.
  • 15
    Trivedi MH, Morris DW, Grannemann BD, Mahadi S. Symptom clusters as predictors of late response to antidepressant treatment. J. Clin. Psychiatry 2005; 66: 10641070.
  • 16
    Hosmer DW, Lemeshow S. Applied Logistic Regression. John Wiley & Sons, New York, 1999.
  • 17
    Forthofer RN, Lee ES, Hernandez M. Biostatistics: A Guide to Design, Analysis, and Discovery. Elsevier Academic Press, Burlington, MA, 2007.
  • 18
    Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J. Outcome definitions and predictors in depression. Psychother. Psychosom. 1998; 67: 266270.
  • 19
    Pande AC, Sayler ME. Severity of depression and response to fluoxetine. Int. Clin. Psychopharmacol. 1993; 8: 243245.
  • 20
    Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C. What constitutes an adequate antidepressant trial for fluoxetine? J. Clin. Psychiatry 1990; 51: 811.
  • 21
    Beasley CM Jr, Nilsson ME, Koke SC, Gonzales JS. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: A meta-analysis of the 20-mg/day dose. J. Clin. Psychiatry 2000; 61: 722728.
  • 22
    Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur. Arch. Psychiatry Clin. Neurosci. 2005; 255: 387400.
  • 23
    Gram L. Fluoxetine. N. Engl. J. Med. 1994; 331: 13541361.
  • 24
    Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. J. Clin. Psychopharmacol. 2002; 22: 4045.
  • 25
    Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960; 23: 5662.
  • 26
    Nierenberg AA, Farabaugh AH, Alpert JE et al. Timing of onset of antidepressant response with fluoxetine treatment. Am. J. Psychiatry 2000; 157: 14231428.
  • 27
    Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am. J. Psychiatry 2006; 163: 19051917.
  • 28
    Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: Systematic review and meta-analysis. Arch. Gen. Psychiatry 2006; 63: 12171223.
  • 29
    Quitkin FM, Petkova E, McGrath PJ et al. When should a trial of fluoxetine for major depression be declared failed? Am. J. Psychiatry 2003; 160: 734740.
  • 30
    Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J. Clin. Psychiatry 2007; 68: 11951205.
  • 31
    Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am. J. Psychiatry 1995; 152: 15001503.